The incretin class has expanded quickly, and the compounds within it are often discussed interchangeably. This guide sets out what actually separates them at the receptor level and what comparative research examines.

What Are Incretins?

Incretins are gut-derived hormones released in response to nutrient intake that potentiate insulin secretion. The two principal endogenous incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both are rapidly degraded by the enzyme DPP-4, giving native half-lives measured in minutes — which is why essentially every research analog in this class is engineered for stability.

The Engineering Problem

Two modifications recur across the class. The first is backbone substitution near the DPP-4 cleavage site, commonly an Aib residue at position eight, which blocks enzymatic cleavage. The second is attachment of a fatty-acid chain, which promotes reversible binding to serum albumin so the peptide is held in circulation and released gradually.

Understanding this shared strategy is useful because it means differences between these compounds are mostly about which receptors they engage, not how they achieve duration.

Comparing by Receptor Coverage

Semaglutide — single agonist at GLP-1. A 31-amino-acid analog with Aib at position eight and a C18 diacid chain.

Tirzepatide — dual agonist at GIP and GLP-1. A 39-amino-acid peptide with a C20 diacid chain.

Retatrutide — triple agonist adding glucagon receptor activity.

Cagrilintide — not an incretin at all. It is an acylated amylin analog acting at amylin and calcitonin receptor complexes, and is included in comparisons because it is frequently studied alongside GLP-1 agonists to examine whether distinct satiety pathways interact.

Why Receptor Coverage Changes the Profile

GLP-1, GIP and glucagon receptors are all class B GPCRs signaling largely through cyclic AMP, but they are expressed in different tissues. GLP-1 receptor activation is associated with glucose-dependent insulin secretion and central satiety signaling. The GIP arm is less settled in the literature, with ongoing debate over whether agonism or antagonism produces the observed metabolic effects. The glucagon arm is associated with increased energy expenditure and hepatic lipid effects.

Because glucagon and GLP-1 have partly opposing effects on glucose handling, adding receptors is not straightforwardly additive. The balance of relative potencies determines the profile, which is why comparative potency measurements matter more than receptor count.

What Comparative Research Examines

Typical study designs measure binding affinity and functional potency at each receptor independently, compare cyclic AMP and beta-arrestin recruitment signatures, examine metabolic endpoints in rodent models, and test whether multi-receptor compounds behave as predicted from single-receptor data. A recurring question is whether observed effects reflect simple summation or receptor cross-talk.

Why Purity and Verification Matter

Reproducibility in peptide research depends on knowing exactly what is in the vial. Sequence-related impurities, truncated fragments and residual synthesis reagents can all influence experimental outcomes, and two preparations nominally of the same compound can behave differently if purity differs. Independent HPLC and mass spectrometry testing establishes both identity and purity, which is why third-party verification is standard practice for research-grade material. All compounds referenced here are supplied as lyophilized powder at greater than 98 percent purity with independent verification.

Summary

The incretin research class shares a common engineering strategy — DPP-4-resistant backbones plus fatty-acid acylation — and differs mainly in receptor coverage, from single through dual to triple agonism. Because the receptors act in different tissues and partly opposing directions, potency balance rather than receptor count shapes the profile. All are intended strictly for laboratory research.

Related Research Peptides

Semaglutide 10mg · Semaglutide 20mg · Tirzepatide 10mg · Tirzepatide 40mg · Retatrutide 10mg · Retatrutide 50mg · Cagrilintide 5mg

Detailed three-way comparison

For laboratory and research use only. Not for human or veterinary use, and not for diagnostic or therapeutic purposes.